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Perceptual benefits from the cochlear prosthesis are
related to the quantity and quality of the patient’s
auditory nerve population. Multiple neurotrophic fac-
tors, such as glial cell line-derived neurotrophic factor INTRODUCTION
(GDNF), have been shown to have important roles in
the survival of inner ear auditory neurons, including
Cochlear implant technology has expanded rapidlyprotection of deafferented spiral ganglion cells
over the last decade. The cochlear implant has pro-(SGCs). In this study, GDNF gene therapy was tested
vided great benefits to patients with profound hearingfor its ability to enhance survival of SGCs after amino-
impairment. The implant sends sound to the speechglycoside/diuretic-induced insult that eliminated the
processor and transforms the acoustic energy into aninner hair cells. The GDNF transgene was delivered
electrical signal that is passed to an electrodeby adenoviral vectors. Similar vectors with a reporter
implanted within the cochlea. The functional state andgene (lacZ) insert served as controls. Four or seven
the number of surviving spiral ganglion cells (SGCs)days after bilateral deafening, 5 ml of an adenoviral
are among the factors that determine the success ofsuspension (Ad-GDNF or Ad-lacZ) or an artificial peri-
the procedure. This article addresses the means oflymph was injected into the left scala tympani of guinea
reducing SGC loss by adenoviral-mediated gene trans-pigs. Animals were sacrificed 28 days after deafening
fer leading to overexpression of glial cell line-derivedand their inner ears prepared for SGC counts. Adeno-
neurotrophic factor (GDNF).viral-mediated GDNF transgene expression enhanced
Following destruction of hair cells in the organ ofSGC survival in the left (viral-treated) deafened ears.
Corti, spiral ganglion cells degenerate (Webster andThis observation suggests that GDNF is one of the
Webster 1981; Sutton and Miller 1983; Jyung et al.survival factors in the inner ear and may help maintain
1989; Nadol 1990; Leake et al. 1991; Otte et al. 1978).the auditory neurons after insult. Application of GDNF
There have been several reports of successful preven-and other survival factors via gene therapy has great
tion or reduction of SGC degeneration, through thepotential for inducing survival of auditory neurons
use of electrical stimulation, GM1 ganglioside, and,following hair cell loss.
in particular, neurotrophins (Hartshorn et al. 1991;
Lousteau 1987; Leake et al. 1991; Miller et al. 1997;
Mitchell et al. 1997; Staecker et al. 1996; Ernfors et al.
Correspondence to: Dr. Yehoash Raphael • Kresge Hearing Research 1995, 1996; Schindler et al. 1995; Shah et al. 1995).
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cochlea and to have an important role in the develop- cochlear aqueduct, inoculation with vectors is techni-
cally feasible. The enclosed anatomy prevents thement of the auditory system (Pirvola et al. 1992, 1994;
spread of viral particles to adjacent tissues. However,Farinas et al. 1994; Jones et al. 1994; Ernfors et al.
cochlear fluid spaces allow diffusible particles, such as1994, 1995; Despres and Romand 1995; Liu et al. 1995;
viruses or proteins, to disperse rapidly throughout theFritzsch et al. 1997, 1999). Studies have also begun to
cochlea. This is especially advantageous for restrictingdefine the effects of providing neurotrophic factors
GDNF gene transfer to the inner ear since GDNF alsoon ear tissues and to determine the changes in the
functions in the kidneys and the enteric nervous sys-inner ear that occur in transgenic mice which do not
tem. Additionally, the blood–labyrinth barrier limitsexpress these survival factors. Some neurotrophins,
systemically administered GDNF concentration in thesuch as BDNF,NT-3, and NGF, have been shown to
inner ear.protect SGCs and hair cells from trauma (Staecker et
Among the different viral vector systems that exist,al. 1996; Miller et al. 1997; Ernfors et al. 1996; Schin-
the adenoviral-mediated gene transfer system offersdler et al. 1995; Shah et al. 1995). By the late stages
several important advantages as a tool for directof embryogenesis, mice lacking the genes for produc-
somatic cell gene delivery in the cochlea. The E1 andtion of both NT-3 and BDNF completely lack type I
E3 genes are deleted, preventing viral DNA replica-and type II spiral ganglion neurons, suggesting that
tion, and high titers of virus stocks are available. Thethese factors are essential for normal development and
adenovirus genome generally does not integrate intomaintenance of spiral ganglion neurons (Ernfors et
the host cell’s chromosome, thus potentially limitingal. 1994, 1995; Farinas et al. 1994).
insertional mutagenesis. Finally, it is possible to infectGDNF, the first member of a new family of trophic
quiescent as well as replicating cells. These advantagesfactors distantly related to the transforming growth
have enabled the development of adenoviral systemsfactor-b superfamily, was initially isolated and cloned
as effective drug delivery devices.as a factor produced by B49 rat glial cells with pro-
Here we report on our studies to test the influencenounced trophic effects on cultured fetal rat midbrain
of the viral-mediated GDNF transgene on SGC survivaldopamine neurons (Lin et al. 1993, 1994). Several
after aminoglycoside/diuretic-induced inner hair cellstudies from a number of laboratories have shown that
degeneration in guinea pigs.GDNF is synthesized by many cell types throughout
the body and affects the development and survival of
a diverse set of neuronal and non-neuronal cells
(Moore et al. 1996; Pichel et al. 1996; Henderson et
MATERIALS AND METHODSal. 1994; Sanchez et al 1996; Buj–Bello et al. 1995;
Trupp et al. 1995). The expression of mRNAs encod-
ing GDNF is present in developing outer hair cells Thirty-two pigmented guinea pigs were used in these
(OHCs) and inner hair cells (IHCs) and in the mature studies. Animals were outbred in the Murphy supplier
IHCs (Ylikoski et al. 1998). The GDNF family receptor colony. All animal experiments were approved by the
a-1 (GFRa-1, formerly GDNFR-a) was detected in spi- University of Michigan Institutional Committee on the
ral ganglion neurons and in their non-neuronal sheath Use and Care of Animals and were performed using
cells (Ylikoski et al. 1998; Stöver et al. 2000). GDNF accepted veterinary standards.
has recently been shown to protect hair cells and SGCs
of the cochlea against various insults (Ylikoski et al.
1998; Shoji et al. 2000; Keithley et al. 1998; Yagi et Adenoviral vectorsal. 1999).
Recombinant viral vectors have proved to be thera- We have used two replication-deficient recombinant
peutically successful in animal models; for example, adenoviruses. Both were based on the human adenovi-
in correcting genetic abnormalities, inhibiting inflam- rus serotype 5 in which three transcriptional regions
matory cascades to reduce brain injury, and providing (E1A and E1B and a portion of the E3) have been
trophic support for neuronal tissues. Studies investigat- deleted. The inserts in both vectors were driven by
ing cochlear gene therapy have been initiated using a the cytomegalovirus (CMV) immediate promoter. The
variety of viral vectors and rodents as the animal model experimental vector contained the human GDNF gene
(Geschwind et al. 1996; Lalwani et al. 1996, 1997, 1998; and was designated Ad-GDNF. The control vector con-
Raphael et al. 1996; Staecker et al., 1998; Weiss et al. tained the E. coli b-galactosidase cDNA and was desig-
1997). The cochlea possesses several advantages as a nated Ad-CMVntlacZ. Both vectors were prepared
target organ for gene transfer. Although it is encased according to standard procedures (Lapchak et al.
in the temporal bone and is relatively isolated except 1997; Akli et al. 1993). Viral suspensions in 10% glyc-
erol were kept at 2808C until thawed for use.through the endolymphatic duct and sac and the
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Procedures to confirm deafening ml of 1% lidocaine HCl was injected subcutaneously
for local anesthesia. The left temporal bone was
Guinea pigs were deafened with a single dose of kana- exposed postauricularly and perforated to reveal the
mycin (400 mg/kg SC). Two hours later, animals were round window. Using a plastic cannula connected to
prepared for cannulation of the jugular vein, as pre- the bent tip of a 30 gauge needle and a 25-ml Hamilton
viously described (West et al. 1973), and infused with syringe, 5ml of an isotonic adenoviral suspension
ethacrynic acid (40 mg/kg IV). Deafening was verified (approximate concentration of 1010 adenoviral parti-
by auditory brainstem response (ABR) audiometry cles per milliliter in sterile normal Ringer’s solution)
and visual assessment of hair cell damage in surface or artificial perilymph (AP) (sterile normal Ringer’s
preparations. ABRs (4-, 12-, and 20-kHz pure tones) solution) was injected into the scala tympani through
were performed twice before deafening (to determine the round window membrane. Animals inoculated
baseline thresholds) and just before sacrifice. Animals with the Ad-GDNF were designated as the experimen-
were anesthetized with a mixture of xylazine (10 mg/ tal group (inoculation 4 days after deafening, N 5 5;
kg IM) and ketamine (40 mg/kg IM), and needle 1 week after deafening, N 5 7), animals inoculated
electrodes were placed subcutaneously. The reference with an Ad-lacZ vector served as the viral control (1
electrode was inserted beneath the pinna of the mea- week after deafening, N 5 4), and those receiving AP
sured ear, the ground beneath the opposite ear, and were the vehicle control (4 days after deafening, N 5
the active electrode beneath the skin on the top of 4; 1 week after deafening, N 5 4). After inoculation,
the head. The stimulus duration was 15 ms, the presen- the bulla was sealed with Durelon and the skin was
tation rate 10/s, and the rise/fall time 1 ms. Around closed with sutures. Subcutaneous postoperative
threshold, responses for 1024 sweeps were averaged administration of 5 ml of 0.9% saline provided rehydra-
at each intensity level, in 5-dB-SPL steps. Threshold tion. In all groups, the right ears were used as noninoc-
was determined by visual inspection of the responses ulated controls.
and defined as the lowest intensity level at which a
clear waveform was visible in the evoked trace. Thresh-
Tissue processingold shifts were calculated for individual animals by
comparing thresholds immediately before sacrifice At the completion of the experiment (28 days after
with the irbaseline thresholds. deafening), the animals were deeply anesthetized, per-
Animals were deeply anesthetized and decapitated, fused intracardially with 2% paraformaldehyde and
and the ears were removed for histological evaluation 2.5% glutaraldehyde, and decapitated, and the ears
just after ABRs. The inner ears were fixed in 4% para- were removed for histological evaluation. The inner
formaldehyde for 2–3 hours. In all animals, the otic ears were postfixed in the same fixative for 2–3 hours.
capsule, lateral wall, and tectorial membrane were Cochleae were decalcified in 3% EDTA with 0.25%
removed, and the bony modiolus with the organ of glutaraldehyde for 2 days. Tissues were then dehy-
Corti was carefully detached at the base of the cochlea. drated in a series of ethanol and embedded in JB-
At this stage, tissues were permeabilized with 0.3% 4 (Electron Microscopy Scientific, Washington, PA).
Triton X-100 in PBS for 10 min, then incubated for Sections were obtained at the midmodiolar area (3
30 min with rhodamine phalloidin (Molecular Probes, mm thick) with every fifth section kept, stained with
Eugene, OR) diluted 1:100 in PBS at room tempera- toluidine blue, and cover-slipped with Permount
ture. After washing, the organ of Corti turns were (Fisher Scientific, Pittsburgh, City, State).
separated from the modiolus, mounted on microscope An unbiased investigator inspected the collection
slides with Crystal/Mount (Biomeda Co., City, State), of sections generated for each cochlea and selected
and examined for hair cell loss to confirm deafening. the slides which had high-quality sections. Sections
Tissue was photographed using a Leica DMRB epiflu- which had folds in the plastic, over- or understaining,
orescence microscope. or uneven thickness were eliminated. From the
remaining high-quality sections, three sections from
each cochlea were randomly chosen for counting.Deafening and viral administration
In the guinea pig cochlea, midmodiolar sections
include seven regions of Rosenthal’s canal. We assessedBilateral deafening was performed in the 24 experi-
mental animals as described above, 4 days or 1 week the number of SGCs in three turns (basal, second, and
third), always on the same side of the modiolus. Theprior to viral injection. Animals were anesthetized with
an intramuscularly administered solution of Rompun chosen slides were given a code name which was blind
to the person who performed the counting. All neu-(xylazine, 10 mg/kg; Bayer, Shawnee Mission, KS) and
Ketalar (ketamine HCL, 40 mg/kg; Parke Davis, Mor- rons present in the section along with their nucleus
were counted. SGC density (SGC number/10,000ris Plains, NJ). Chloramphenicol sodium succinate (30
mg/kg IM) was administered as prophylaxis, and 0.5 mm2) was calculated using Meta-Morph computerized
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FIG. 1. A. A phalloidin-labeled
organ of Corti specimen taken from
the second turn of a cochlea 4 days
after the deafening procedure. The
focal plane is that of the inner hair
cells, demonstrating a complete
hair cell loss and typical scar forma-
tion (arrows). Each arrow points to
the center of a scar, in two adjacent
scars. Scars in the region of the
outer hair cells can also be seen
(arrow heads). B. Midmodiolar sec-
tion of a guinea pig cochlea 28 days
after deafening stained with tolu-
idine blue. Both inner (arrowhead
on left) and outer hair cells (arrow-
head on right) are missing. Scale
bars: (A) 20 mm, (B) 10 mm.
image analysis system (Miller et al. 1997; Komeda et were then processed for GDNF-specific immunocyto-
chemistry. The fixed cells were permeabilized withal. 1999). The entire area of Rosenthal’s canal in each
counted section was circled for the purpose of area 0.3% Triton X-100 for 10 minutes, incubated in a poly-
clonal anti-GDNF antibody (Santa Cruz Biotechnologycalculation (performed by the software). The bound-
aries of the canal were drawn at the interface between Inc. Santa Cruz, CA) for 60 minutes, rinsed in buffer
and incubated with rhodamine conjugated goat–the bone and the soft tissue within Rosenthal’s canal.
After counting the three sections of each cochlea, the antirabbit secondary antibody (Jackson ImmunoRe-
search Laboratories, Inc. West Grove, PA) for 30average value of the SGC density was calculated for
each cochlea. Sigma State statistical software, (SPSS minutes. Following a final rinse, cells were mounted
on microscope slides with Crystal/Mount (Biomedia,Science, Chicago, IL) was used for statistical analysis.
Comparisons and statistical significance calculations Foster City, CA). The two negative controls were cells
that were not exposed to the Ad-GDNF and cells thatof differences between inoculated and control (nonin-
oculated) ears were made with two-sample t tests. Com- were treated with the vector, but the primary antibody
was omitted from the reaction. Samples were analyzedparisons between several groups were accomplished
by ANOVA. We also examined 4 nontreated cochleae and photographed with a Leica DMRB epifluores-
cence microscope.with no deafening or inoculation and compared
between experimental animals and nontreated (nor-
mal) cochleae (SGC percent survival 5 deafened ears/
normal 3 100). RESULTS
DeafeningAssay of vector activity
To test the ability of the Ad-GDNF to mediate produc- The deafening procedure used for these experiments
was tested on a dedicated group of six animals thattion of GDNF in transduced cells, we performed an
assay on cultured guinea pig fibroblasts. We used a were killed four days (N 5 3) and one week (N 5 3)
after deafening. The deafening procedure resulted infibroblast cell line (kindly provided by Dr. Thomas
Carey) that had previously been described(Ptok et al. a complete or nearly complete loss of both IHCs and
OHCs. In two animals from the four-day group, a few1991). Cells were resuspended with trypsin–EDTA
(Gibco-BRL, Grand Island, NY) and seeded on pre- OHCs remained at the apex, and in the remaining
animals, no remaining hair cells could be observedcleaned coverslips. The coverslips were placed in a six-
well culture dish and maintained in DMEM (Gibco- (Fig. 1A). Deafening was also confirmed in these ani-
mals by ABR testing. All animals (n 5 6) had thresholdBRL, Grand Island, NY) with 10% FBS at 378C and
5% C02. Once cells had reached a near-confluence shifts over 75 dB SPL across the test frequencies 1
week and 4 days after the deafening procedure.stage, the Ad-GDNF (1 3 1012 pfu/ml) solution was
added into the culture. Four hours later, it was rinsed In addition to the six animals that were used for
deafening verification, the morphology of the organby replacing the culture media. Twenty-four hours
later, the coverslips were removed from the incubator, of Corti could also be observed in the midmodiolar
section used to count SGCs in the experimentalbriefly rinsed in PBS, and fixed in 4% paraformalde-
hyde in phosphate buffer for 1 hour. The specimens groups. All cochlear sections from the experimental
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FIG. 2. Light micrographs of
Rosenthal’s canal at the basal turn
of specimens taken from deafened
animals (experimental groups).
Midmodiolar sections of the basal
part of the cochleae that received
Ad-GDNF (A: inoculated ear, left:
B: control ear, right), Ad-lacZ (C:
inoculated ear, left: D: control ear,
right), and AP (E: inoculated ear,
left: F: control ear, right) stained
with toluidine blue. The Ad-GDNF-
inoculated ear (A) has better preser-
vation of SGCs after aminoglyco-
side-induced trauma compared
with the noninoculated right ear (B).
In other treated ears (Ad-lacZ- and
AP-inoculated ears, C and E ) and
noninoculated ears (right) (B, D,
and F ), there is a severe loss of spiral
ganglion neurons. Scale bar-25 mm.
groups showed a complete loss of IHCs from base to AP-inoculated ears in the basal turn ( p , 0.05) but
not in the middle and upper turns (Figs. 3 and 4).apex (Fig. 1B).
Inoculation 1 week after deafening. In animals deaf-
ened 1 week before the inoculation, the extent of
neuronal degeneration in the control cochleae (11SGC density
deafened, nontreated; 4 treated with AP) was similar
from base to apex (averaging 46.1%–60.3% SGC sur-The control cochleae (Ad-lacZ, AP, or noninoculated
vival). Although there was some quantitative variabilityears) showed a severe loss of spiral ganglion neurons
among the animals receiving Ad-GDNF, SGC density(Fig. 2) as previously demonstrated after similar
in all left ears receiving Ad-GDNF was higher in thetrauma to the organ of Corti (Komeda et al. 1999;
basal and middle turns than in the opposite ears andMiller et al. 1997).
the control ears (Figs. 5 and 6). In some left earsInoculation 4 days after deafening. In animals deafened
receiving the Ad-lacZ, the density of SGCs in the basal4 days before the inoculation, the extent of neuronal
turn (averaging 26.8% survival) was less than in thedegeneration in the control cochleae (nine deafened,
opposite ears and the other control ears. In the middlenontreated right cochleae; four left cochleae treated
and basal turns, but not in the upper turn, there waswith AP) gradually became more severe toward the
a statistically significant ( p , 0.05) survival of SGCs forbase. There was a statistically significant SGC survival
Ad-GDNF-inoculated ears at 28 days after deafeningfor Ad-GDNF-inoculated ears at 28 days after deafen-
ing compared with the noninoculated ears and the compared with the noninoculated ears (Fig. 5). There
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after deafening (upper turn, 65.4%; middle turn,
65.9%; basal turn, 88.6%). There is a trend for higher
density of cells in the 4-day group. The data are summa-
rized in Table 1.
Ad-GDNF tested in guinea pig fibroblast culture
Cells in the two negative controls did not show immu-
noreactivity with the GDNF-specific antibody (data not
shown). In contrast, the cultures that were treated with
the Ad-GDNF contained cells that stained positive for
the antibody (Fig. 7).
DISCUSSION
This article describes a successful gene transfer proce-
FIG. 3. The average spiral ganglion neuron density in the Ad-GDNF-
dure in the inner ear in vivo to protect SGCs aftertreated group (4 days after deafening, N 5 5). The inoculated (left) ears
aminoglycoside/diuretic-induced cochlear insult. Theshow statistically significant protection compared with noninoculated
(right) ears (N 5 4) in the basal turn ( p, 0.05). kanamycin/ethacrynic acid deafness protocol yields a
severe loss of hair cells in the entire cochlea and pro-
found hearing loss. The loss of IHCs leads to a second-
ary degeneration of SGCs, as previously determinedwere also statistically significant differences between
Ad-GDNF groups, and bothAd-lacZ and AP groups’ (Webster and Webster 1981; Komeda et al. 1999; Miller
et al. 1997).ears in the middle and basal turns ( p , 0.05) but not
in the upper turn (Fig. 6). There was a trend toward It remains unknown how the degeneration of deaf-
ferented spiral ganglion neurons occurs. It seems rea-lower SGC density in the Ad-lacZ-inoculated ears than
in the AP-inoculated ears in the basal portion of the sonable, however, that disruption of the trophic
support and neuronal interaction between the haircochlea (Fig. 6).
The average SGC percent survival in the ears inocu- cells and SGCs would be associated with the degenera-
tion of SGCs. Neurotrophic factors are important forlated with Ad-GDNF 4 days after deafening (upper
turn, 70.7%; middle turn, 61.5%; basal turn, 89.4%) the development and maintenance of the nervous sys-
tem, as well as the inner ear. These factors promoteis rather similar to that of the ears inoculated 1-week
FIG. 4 Comparison between the Ad-GDNF and the AP treatment than the AP-inoculated ears in the basal turn ( p , 0.05). The contralat-
is demonstrated by presenting the mean spiral ganglion neuron den- eral (right) ears have a tendency for higher neuronal density in the
sity (and SD) among these groups in the 4-day interval animals. The Ad-GDNF group compared with the AP group.
SGC density in the Ad-GDNF-inoculated ears is significantly higher
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reported. The chronic infusion of BDNF, NT-3, NGF,
and GDNF can provide SGC survival after IHC insults
(Ernfors et al. 1996; Staecker et al. 1996; Shah et al.
1995; Miller et al. 1997; Ylikoski et al. 1998). Viral-
mediated gene transfer of BDNF using a replication-
defective herpes simplex-1 vector has been shown to
have a significant positive effect on the survival of
denervated spiral ganglion neurons in the mouse
(Staecker et al. 1998). Interaction between two or
more neurotrophic factors is likely to influence the
spiral ganglion. For instance, it has been shown that
GDNF promotes survival of axotomized corticospinal
neurons via BDNF (Giehl et al. 1998). It is therefore
possible that GDNF may influence the spiral ganglion
indirectly, via upregulating expression of BDNF or
other neurotrophic factors.
FIG. 5 The average spiral ganglion neuron density (number of cells/ GDNF is a distantly related member of the trans-
10,00 mm) and S.D. (error bar) in the Ad-GDNF-treated group (1 forming growth factor-b superfamily, which acts as aweek after deafening, N 5 4). A comparison between the SGC density
potent survival factor for both the peripheral and thein all inoculated (left) vs. noninoculated (right) ears demonstrates
central nervous system. GDNF is a potent survival fac-statistically significant protection in the middle and basal turns
( p , 0.05). tor for a variety of nerve cells, such as dopaminergic
neurons (Choi–Lundberg et al. 1997; Gash et al.
1996), motoneurons (Henderson et al. 1994), sensory
or autonomic neurons (Buj–Bello et al. 1995), as wellneuronal survival and can prevent the neuronal degen-
as corticospinal neurons (Giehl et al. 1998). GDNF iseration associated with injury, toxin exposure, and
also an essential factor for the development of theneurodegenerative disease. Several studies using the
enteric nervous system and the kidney duringosmotic pump infusion for chronic delivery of neuro-
trophic factors into the rodent cochlea have been embryogenesis (Moore et al. 1996; Pichel et al. 1996;
FIG. 6 The mean spiral ganglion neuron density among groups and S.D. (error bar) (1 week after deafening). The SGC density in the Ad-
GDNF-inoculated ear is significantly higher than those of the Ad-lacZ and AP inoculated ears in the middle and basal turn ( p , 0.05).
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TABLE 1
Density of SGC in the experimental and control groups
SG cell survival % (experimental ear/normal ear 3 100)
Inoculated ear Noninoculated ear
Upper Middle Base Upper Middle Base
4 days after deafening
Ad-GDNF 70.66 61.50 89.45 57.29 51.51 50.85
AP 37.23 35.08 42.09 42.19 30.14 43.10
7 days after deafening
Ad-GDNF 65.44 65.95 88.55 58.99 44.77 56.91
Ad-Lac Z 48.87 33.36 26.82 51.98 31.80 40.42
AP 48.60 46.59 54.02 46.10 47.04 60.34
that the trauma in the cochlea leads to upregulation
of GDNF or its receptors. An alternative explanation is
that GDNF might act on SGCs through an unidentified
pathway or different receptors, e.g., GFRa-2, to which
GDNF binds with lower affinity.
Once the protective pathway is activated, GDNF is
likely to prevent apoptosis in the spiral ganglion.
TUNEL positive cells were demonstrated in the SGCs
in the aged gerbil cochlea (Zheng et al. 1998). Pai et
al. (1998) showed apoptosis of cochlear spiral ganglion
neurons after nitric oxide exposure by DNA fragmen-
tation and the TUNEL method. These studies suggest
that spiral ganglion neurons degenerate by undergo-
ing active cell death. GDNF has been shown to suppress
apoptosis of developing and postnatal substantia nigraFIG. 7 Epifluorescence image of cultured guinea pig fibroblasts that
were incubated with the Ad-GDNF vector and stained with a GDNF- dopamine neurons in vitro (Burke et al. 1998; Clarkson
specific antibody. The nuclei are negative whereas the cytoplasm et al. 1997) and is likely to have similar capability in
stains positively with this antibody. Scale bar-10 mm. the spiral ganglion in vivo. More work will be necessary
to understand the protective mechanism of GDNF on
the denervated spiral ganglion.Sanchez et al. 1996). In addition, GDNF has been
At this stage, the transgenic expression of GDNF isshown to promote neurite outgrowth in the enteric
unregulated. The data generated with the culturednervous system (Schafer and Mestres 1999) and moto-
guinea pig fibroblasts demonstrate the ability of theneurons (Zurn et al. 1994).
vector to transduce guinea pig fibroblasts and lead toThe mechanism of GDNF signaling involves two
synthesis of the gene product. Using adenovirus vec-receptors. It first binds to the Ret receptor, then to a
tors with a reporter gene insert, we have previouslycoreceptor, a tyrosine kinase and glycosylphosphatidyl-
shown that the transduced inner ear cells were mostlyinositol (GPI)-linked receptor named GFRa (Jing et
fibrocytes lining the perilymphatic space (Yagi et al.al. 1996; Treanor et al. 1996; Durbec et al. 1996).
1999). Based on these two sets of data we speculatemRNAs encoding GDNF have been detected in the
that inoculating the inner ear with Ad-GDNF resulteddeveloping OHCs and IHCs and in the mature IHCs
in transduction of the connective tissue cells lining(Ylikoski et al. 1998). The GFRa-1 has been detected in
the perilymphatic space. These cells, in turn, secretedthe spiral ganglion neurons and in their non-neuronal
GDNF into the perilymph, making it accessible to thesheath cells during development and in adult animals.
spiral ganglion.Using RT-PCR, Stöver et al. (2000) demonstrated that
In reporter gene experiments, the transduced cellsGDNF, GFR-1, and c-ret mRNA were detected in the
were seen mostly in the basal turn and lower secondspecific cochlear tissues, including the modiolus. The
turn. Although these cells secreted GDNF which dif-level of Ret expression in the normal inner ear was
fused throughout the cochlea from base to apex, therather low (Stöver et al. 2000). However, to explain
the protective effect of exogenous GDNF, it is possible protective effects were more robust toward the basal
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